Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.

Trial Details

NCT ID
NCT06145308
Phase
PHASE2
Sponsor
Peking Union Medical College
Status
RECRUITING
Cancer Type
Salivary Gland Head and Neck Cancer
Interventions
  • Cohort 1 (HER2-positive, RC48-ADC)
  • Cohort 2 (NTRK-fusion or NTRK-mutant)
  • Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
  • TROP2 ADC
  • TKI
  • Albumin-paclitaxel + platinum
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients with histopathologic diagnosis of salivary gland carcinoma
  • The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemical staining.
  • ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment;
  • Age 18 or older - no upper limit;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Salivary Gland Head and Neck Cancer Trials on Trialify →